Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib

Inclusion Criteria: * The informed consent form must be signed before any study specific tests or procedures are done * Male or female patients aged 18 years and older at the first screening visit * Histologically confirmed diagnosis of advanced or metastatic non adipocyte soft tissue sarcoma (STS) * Suitable for treatment with pazopanib in an in-label prescription * Patients with a life expectancy of at least 6 months * Eastern Co-operative Oncology Group (ECOG) performance status 0-2 * Adequate organ function as given in Table 1 * For patients with previous anthracycline therapy a normal heart function needs to be documented with an left ventricular ejection fraction (LVEF) of minimal 50% (echocardiogram) * Patients must be willing and able to fill in the Quality of live (QoL) questionnaires using a tablet PC * Ability to understand and follow study-related instructions * Confirmation of the subject's health insurance coverage prior to the first visit Exclusion Criteria: * Pretreatment with pazopanib * Contraindications according to the local Summary of product characteristics ( SmPC) of Votrient® * Patients having to following STS specific tumors * adipocyte sarcoma including all subtypes, * all rhabdomyosarcoma, which are not alveolar or pleomorph * Chondrosarcoma * Osteosarcoma * Ewing-tumors, i.e. primitive neuroectodermal tumors (PNET), gastrointestinal stromal tumor (GIST) * Dermatofibrosarcoma protuberans * inflammatory myofibroblastic sarcoma * Malignant mesothelioma * Mixed mesenchymal and epidermal tumors of the uterus Other malignant underlying diseases with the exception of the following: * Free of disease for at least 3 years * Completely resected, non-melanoma skin cancer * Successfully treated carcinoma in situ * Patients with metastases of the central nervous system (CNS) at screening, which are asymptomatic AND do not require treatment with steroids or enzyme-inducing anticonvulsant drugs * Patients with metastases of the CNS, which are already treated (operation and/or radiotherapy, radiosurgery or gamma-knife) * Major surgery or trauma within 28 days before the first dose of study medication and / or presence of a non-healing wound, fracture, or ulcer * Clinical indications of an active bleeding or a bleeding diathesis * Known endobronchial lesions or lesions that infiltrate the large pulmonary artery * Hemoptysis of\> 2.5 mL within 8 weeks before the first dose of study drug * Existing uncontrolled infection * Heart rate-corrected QT-time according to the Fridericia's-formula (QTcF) 450 ms in males and 460 ms in females * History of one or more of the following cardiovascular diseases within the last 6 months: * Cardiac angioplasty or coronary stent * Myocardial infarction * Unstable angina pectoris * Coronary artery bypass surgery * Symptomatic peripheral arterial disease * Cardiac insufficiency New York Heart Association (NYHA) functional dass III or IV * Poorly controlled hypertension defined as systolic blood pressure 140 mmHg or diastolic blood pressure 90 mmHg * History of cerebrovascular disease, including transient ischemic attacks (TIA), pulmonary embolism or untreated deep vein thrombosis within 6 months prior to study entry. Patients with deep vein thrombosis who have received therapeutic anticoagulation for a minimum of 6 weeks might be included in the study. * Clinically significant gastrointestinal changes that increase the risk of gastrointestinal bleeding * Clinically significant gastrointestinal changes that may affect the absorption of the study drugs * Treatment with any of the following anti-neoplastic therapies: * Irradiation or Tumor embolization within 14 days prior to the first dose of study drug * Chemotherapy, immunotherapy, biological therapy, study medication or hormonal therapy within 14 days or 5 half lives of substance (whichever is langer) prior to the first dose of study drug * If the discontinuation of prohibited medication (see Section 6.9) at least 14 days or 5 half-lives of substance (whichever is langer) prior to the first dose of pazopanib is medically not acceptable or refused by the patient * A history of hypersensitivity to any of the study drugs or their ingredients or to drugs with similar chemical structure * Addiction or other diseases that preclude the patient from appropriately assessing the nature and scope as well as possible consequences of the clinical trial * Pregnant or breast-feeding women * Women of childbearing potential unless women who meet the following criteria: * Post-menopausal (12 months natural amenorrhea without any application of a hormonal contraceptive or hormonal substitution therapy)) * Postoperatively (6 weeks after bilateral ovariectomy with or without hysterectomy) * Regular and correct use of a contraceptive method with error rate \<1% per year such as implants, depot injections, oral contraceptives or intrauterine devices during treatment and up 6 months after end of treatment * Sexual abstinence * Vasectomy of the partner * Men of sexual activity with women of childbearing potential who are not willing to use an effective barrier method of contraception during and up to 6 months after the end of therapy